The clinical course and outcome of COVID-19 are highly variable, ranging from
asymptomatic infections to severe disease and death. Understanding the risk factors of …

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the 29
causative pathogen of Coronavirus disease 2019 (COVID-19), has resulted in over 650 30 …

Respiratory mucosal immunity induced by vaccination is vital for protection from coronavirus
infection in animal models. In humans, the capacity of peripheral vaccination to generate …

Background Epidemiological studies are necessary to explore the effect of current
pneumococcal conjugate vaccines (PCVs) against antibiotic resistance, including the rise of …

Ongoing surveillance after pneumococcal conjugate vaccination (PCV) deployment is
essential to inform policy decisions and monitor serotype replacement. We report serotype …

Introduction Pneumococcal disease (PD) significantly contributes to morbidity and mortality,
carrying substantial economic and public health burden. This article is a targeted review of …

Worldwide, the COVID-19 pandemic caused by SARS-CoV-2 has enormously impacted
healthcare systems, especially in low and middle-income countries. Coinfections with …

Background Streptococcus pneumoniae interacts with numerous viral respiratory pathogens
in the upper airway. It is unclear whether similar interactions occur with severe acute …

While populations at risk for severe SARS-CoV-2 infections have been clearly identified,
susceptibility to the infection and its clinical course remain unpredictable. As the …

Streptococcus pneumoniae is a bacterial pathogen exclusive to humans, responsible for
respiratory and systemic diseases. Pneumococcal protein vaccines have been proposed as …